Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Jessica K. Altman, Yasmin Abaza, Michael Keng, Abhishek Maiti, Jamie Koprivnikar, Shoshi Tessler, Chen Blumberg, Liat Flaishon, Ruth Ben Yakar

Blood (2023) 142 (Supplement 1): 5970.

https://doi.org/10.1182/blood-2023-185694

Published: 2023

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

Shoshi Tessler, PhD, Inbal Mishalian, PhD, Ronny Peri-Naor, PhD, Stela Gengrinovitch, PhD, Raphael Mayer, PhD, Ruth Ben Yakar, PhD, Amnon Peled, Liat Flaishon, PhD MD

Blood (2018) 132 (Supplement 1): 1451.

https://doi.org/10.1182/blood-2018-99-112092

Published: 2018

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions

Liat Flaishon, Gili Hart, Einat Zelman, Christine Moussion, Valentin Grabovsky, Guy Lapidot Tal, Sara Feigelson, Raanan Margalit, Alon Harmelin, Tamar Avin-Wittenberg, David Shoseyov, Ronen Alon, Jean-Philippe Girard, Idit Shachar

Blood (2008) 112 (13): 5016–5025.

https://doi.org/10.1182/blood-2007-12-129122

Published: 2008

Includes: Supplemental data

Journal Articles

CD74 induces TAp63 expression leading to B-cell survival

Frida Lantner, Diana Starlets, Yael Gore, Liat Flaishon, Ayala Yamit-Hezi, Rivka Dikstein, Lin Leng, Richard Bucala, Yossy Machluf, Moshe Oren, Idit Shachar

Blood (2007) 110 (13): 4303–4311.

https://doi.org/10.1182/blood-2007-04-087486

Published: 2007

Journal Articles

Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration

Liat Flaishon, Shirly Becker-Herman, Gili Hart, Yoram Levo, William A. Kuziel, Idit Shachar

Blood (2004) 104 (4): 933–941.

https://doi.org/10.1182/blood-2003-11-4013

Published: 2004

NARROW

Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions

CD74 induces TAp63 expression leading to B-cell survival

Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only